Šīs tīmekļa vietnes satura kvalitātes uzlabošanai un pielāgošanai lietotāju vajadzībām tiek lietotas sīkdatnes - tai skaitā arī trešo pušu sīkdatnes. Turpinot lietot šo vietni Jūs piekrītat sīkdatņu lietošanai.
JSC Olainfarm increases profitability and earns 7.5 million euros in nine months
Emitents Olainfarm, AS (213800WCG52W62ENOP27)
Veids 3.1. Papildu regulētā informācija, kas ir jāatklāj saskaņā ar dalībvalsts tiesību aktiem
Valoda EN
Statuss Publicēts
Versija
Datums 2018-11-30 17:25:33
Versijas komentārs
Teksts

Unaudited consolidated Income Statement of JSC Olainfarm for nine months of 2018 shows that the sales of the Group have reached 89.5 million euros, which is a slight decrease by 1% compared to the same period of 2017. At the same time, the company managed to increase its profitability - in the nine months of this year, JSC Olainfarm has earned 7.5 million euros, which is an increase of 13% over the nine months of 2017.

In nine months of 2018, sales volumes continued to increase in all of its major outlets, with the exception of Russia and Kazakhstan, where sales fell by 7% and 14% accordingly. Projected Russian ruble fluctuations impacted planned decrease in sales volumes in Russia, while the increased presence in both Latvian and Belarusian markets had a positive effect on a significant increase in sales in these markets.

The biggest sales increase during the 9 months of 2018 was achieved in Tajikistan, where sales grew by 64%, and in Belarus, where sales increased by 42%. Considerable sales increase (by 17%) was also achieved in Latvia, which resulted in total sales in Latvia being comparable to those of Russia. In total in top 10 of the markets of the Group during this 9-month period The Netherlands and Turkmenistan were replaced by Poland and Tajikistan.  Major sales markets of Olainfarm in 9 months of 2018 were Russia, Latvia, Belarus and Ukraine. In reporting period, the Company was selling its products to 50 markets worldwide.

Although the sales in nine months of 2018 slightly lagged behind last year achievement, the Company managed to increase its earnings by more than 850 thousand euros. Major positive factor was that write offs of long-term assets during these nine months were smaller by more than 1.6 million euros, while the major negative change was an increase of COGS by one million euros.

While analyzing the activities of the Olainfarm Group in the 3rd quarter, it should be noted that this 3rd quarter in terms of profit is the most successful third quarter for the Company since 2015. Even despite foreign exchange loss increasing by almost 200 thousand euros, the net profit of third quarter reached 1.7 million euros, which represents an increase of 86% compared to the third quarter of 2017. Major factors influencing the profit increase were write offs of long-term investments being by 700 thousand smaller and write offs of other assets being by 400 thousand smaller than one year ago.

During the 3rd quarter of 2018, compared to the 3rd quarter of 2017, sales of the Company shrunk by less than 0.02% and reached 27.661 million euros, making this third quarter still one of the most successful in terms of sales in corporate history. Despite reduced sales to WHO program, the company has actually managed to repeat the sales volume of last year’s third quarter.

Compared to 9 months period of 2017, this year some significant changes have occurred to the sales structure of bestselling products of Olainfarm.  Remantadine and PASA are replaced by Meldonium and Memantine, Share of Noofen, soluble Furaginum and Etacizin have significantly increased, while share of Adaptol in sales of Olainfarm products has experienced some considerable reduction.

Annual meeting of shareholders of JSC Olainfarm, convened on June 5, 2018 approved operating plan of the Group for 2018.  According to it, sales of the Group in 2018 are planned to be 130 million euros, but the net profit will reach 11.5 million euros.  According to this unaudited report for nine months of 2018, during this period 69% of annual sales target and 65% of annual profit target is met. Management of the Company does not expect the actual revenues and earnings of the company to show any significant deviations from approved. guidance.

 

Condensed Consolidated Statement of Financial Position

 

 

Group

   

30.09.2018

31.12.2017

   

EUR '000

EUR '000

 

     ASSETS

   

NON-CURRENT ASSETS

   

Intangible assets

          36 734

          37 034

Property, plant and equipment

          42 844

          41 892

Investment properties

            3 501

            3 526

Financial assets

            1 066

            2 609

 

TOTAL NON-CURRENT ASSETS

          84 145

          85 061

CURRENT ASSETS

   

Inventories

          26 358

          24 161

Receivables

          32 267

          34 049

Cash

            4 002

            3 158

 

TOTAL CURRENT ASSETS

          62 627

          61 368

TOTAL ASSETS

        146 772

        146 429

     
 

         

 EQUITY AND LIABILITIES

   

EQUITY

   

Share capital

          19 719

          19 719

Share premium

            2 504

            2 504

Other components of equity

              (157)

                (74)

Retained earnings

          79 802

          75 675

 

TOTAL EQUITY

        101 868

          97 824

LIABILITIES

   

Non-current liabilities

   

Borrowings

            9 523

          15 878

Deferred income

            2 827

            2 347

 

Total Non-Current Liabilities

          12 350

          18 225

Current liabilities

   

Borrowings

          15 974

          14 013

Trade payables and other liabilities

          14 608

          15 892

Dividends payable

            1 549

                    -

Deferred income

               423

               475

 

Total Current Liabilities

          32 554

          30 380

 

TOTAL LIABILITIES

          44 904

          48 605

TOTAL EQUITY AND LIABILITIES

        146 772

        146 429

 

Consolidated statement of comprehensive income

Group

Group

 

Q3 2018

Q3 2017

M9 2018

M9 2017

 

EUR '000

EUR '000

EUR '000

EUR '000

Net revenue

       27 661

       27 665

       89 505

       90 384

Cost of goods sold

      (10 909)

      (10 921)

      (35 804)

      (34 851)

Gross Profit

       16 752

       16 744

       53 701

       55 533

Selling expense

        (8 534)

        (8 377)

      (26 715)

      (27 008)

Administrative expense

        (5 684)

        (5 423)

      (17 115)

      (16 872)

Other operating income

            542

            732

         1 947

         1 753

Other operating expense

           (656)

        (1 862)

        (2 460)

        (3 460)

Share of profit of an associate

                8

              10

              83

              70

Financial income

              18

              50

              57

            206

Financial expense

           (703)

           (564)

        (1 794)

        (1 904)

Profit Before Tax

         1 743

         1 310

         7 704

         8 318

Corporate income tax

             (73)

           (398)

           (250)

        (1 806)

Deferred corporate income tax

               (2)

             (17)

                 -

              86

PROFIT FOR THE REPORTING PERIOD

         1 668

            895

         7 454

         6 598

Other comprehensive income for the reporting period

           (119)

                 -

             (83)

                 -

Total comprehensive income for the reporting period

         1 549

            895

         7 371

         6 598

Total comprehensive income attributable to:

       

The equity holders of the Parent Company

         1 549

            896

         7 371

         6 597

Non-controlling interests

                -

              (1)

                -

                1

         

Basic and diluted earnings per share, EUR

           0.12

           0.06

           0.53

           0.47

 

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top - quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Unaudited consolidated 9 months Income Statement attached.

 

 

Information prepared by:

Inga Krukle
Member of the Management Board
JSC Olainfarm
Phone +371 28698449
Email: Inga.krukle@olainfarm.com

 

 

Pielikumi
Olainfarm_lll_2018_consolidated FS_ENG.pdf (1570.55 kB)